Diabetes drug shows promise for kidney protection in new study
NCT ID NCT06291155
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at how an FDA-approved diabetes drug, Canagliflozin (Invokana), might protect the kidneys in people with type 2 diabetes. Twenty adults aged 18-80 with type 2 diabetes for at least 3 years will take the drug daily for 6 months. Researchers will use kidney biopsies and MRIs to see if the drug helps prevent kidney damage.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Canagliflozin (Invokana), an SGLT2 inhibitor drug
What this could lead to
If successful, this could reveal exactly how SGLT2 inhibitors protect the kidneys in type 2 diabetes, potentially leading to better treatments.
What could go wrong
This is a very small, early-phase study with only 20 participants, so results may not apply to everyone. The study involves invasive kidney biopsies, which carry some risk.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Michigan
RECRUITINGAnn Arbor, Michigan, 48109, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact